Background: Interim PET after two ABVD cycles (iPET2) predicts treatment outcome in classical Hodgkin's lymphoma. To test whether an earlier assessment of chemosensitivity would improve the prediction accuracy, we launched a prospective, multicenter observational study aimed at assessing the predictive value of iPET after one ABVD (iPET1) and the kinetics of response assessed by sequential PET scanning.
Background: Interim PET after two ABVD cycles (iPET2) predicts treatment outcome in classical Hodgkin's lymphoma. To test whether an earlier assessment of chemosensitivity would improve the prediction accuracy, we launched a prospective, multicenter observational study aimed at assessing the predictive value of iPET after one ABVD (iPET1) and the kinetics of response assessed by sequential PET scanning.
Patients and methods:
Consecutive patients with newly diagnosed classical Hodgkin's lymphoma underwent interim PET scan after one ABVD course (iPET1). PETs were interpreted according to the Deauville score (DS) as negative (À) (DS 1-3) and positive (þ) (DS 4, 5) . Patients with iPET1 DS 3-5 underwent iPET2.
Results: About 106 early (I-IIA) and 204 advanced (IIB-IV) patients were enrolled between January 2008 and October 2014. iPET1 was (À) in 87/106 (82%) or (þ) in 19/106 (18%) of early, and (À) in 133/204 (65%) or (þ) in 71/204 (35%) of advanced stage patients, respectively. Twenty-four patients were excluded from response analysis due to treatment escalation. After a median follow-up of 38.2 (3.2-90.2) months, 9/102 (9%) early and 43/184 (23%) advanced patients experienced a progression-free survival event. At 36 months, negative and positive predictive value for iPET1 were 94% and 41% (early) and 84% and 43% (advanced), respectively. The kinetics of PET response was assessed in 198 patients with both iPETs. All 116 patients with iPET1(À) remained iPET2(À) (fast responders), 41/82 with IPET1(þ) became iPET2(À) (slow responders), and the remaining Introduction 18-F-Fluoro-D-deoxyglucose Positron Emission Computed Tomography (FDG-PET/CT) is used both in clinical trials and in daily practice to assess the interim response to treatment in classical Hodgkin's lymphoma (cHL) patients [1] . Based on the experience gained with gallium-67 scintigraphy [2] , interim PET (iPET) was carried out in initial studies after one, two or even three cycles of chemotherapy [2] [3] [4] . The highly predictive values (PV) of iPET after two ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) cycles (iPET2) suggested by Hutchings et al. [5] in 2006 was established by Gallamini et al. in 2007 [6] . However, information based on systematic sequential scanning on the kinetics of very early response of HL to chemotherapy was lacking. Therefore in 2008, the Polish Lymphoma Research Group (PLRG) launched a prospective multicenter observational study aimed at assessing the overall PV of very early PET response after the first ABVD cycle (iPET1). The primary end point of the study was the 3-year progression-free survival (3-Y PFS) of iPET1 negative patients with a goal of 95% for early and 90% for advanced stage patients. The secondary end point was the kinetics of response assessed by sequential FDG-PET scanning after first and second ABVD cycle.
Materials and methods

Patients
The protocol was approved by the Institutional Review Board of the Medical University of Gdansk and registered by PLRG as the PLRG-11 trial [7] . The study was conducted in 11 hemato-oncology centers in Poland between January 2008 and October 2014 and all newly diagnosed patients with classical HL were eligible. Before therapy, all patients signed written informed consent and underwent initial staging according to Cotswolds criteria [8] , supplemented by FDG-PET/CT.
Treatment
Patients with early stage disease (I-IIA) were treated with 2-4 cycles of ABVD followed by radiotherapy (RT) to the initially involved lymph nodes/nodal areas, or with six cycles of ABVD. Patients with advanced stage disease (IIB-IV) were treated with 6-8 cycles of ABVD, with or without consolidation RT. No treatment change was permitted based on iPET results.
PET/CT scans
Two iPET scans were carried out 11-13 days after the end of the first or second ABVD course, respectively. After the first interim analysis in 2009 on the first 52 enrolled patients, which demonstrated that all iPET1(À) patients were also iPET2(À), the protocol was amended, allowing to limit iPET2 only to patients with PET1 with a Deauville score of 3 to 5. The details of PET scanning are presented in the supplementary material, available at Annals of Oncology online.
Treatment response evaluation and follow-up
Final treatment response assessment including FDG-PET/CT was carried out according to the International Harmonization Project criteria [9] . Complete response (CR) was defined by a negative PET scan, with or without a negative CT scan, without the need of second-line treatment. Progression was defined as objective evidence of disease recurrence during treatment, whereas relapse as disease recurrence after the end of firstline treatment, confirmed, whenever possible, by a diagnostic biopsy, followed by second-line treatment. Patients were addressed to follow-up with clinical assessment every 3-4 months for 2 years and yearly afterward with PET/CT carried out only on clinical indication.
Image analysis
The details of the image analysis are presented in the supplementary ma terial, available at Annals of Oncology online.
Statistical methods
Progression-free survival was the primary end point. Accepted precision for the study expressed as half of the length of 95% confidence interval (CI) was set to the range between 4% and 5%. The study was powered to demonstrate a 3-Y PFS of PET1-negative patients of 95% and 90% for early and advanced stage patients, respectively, with a required minimum sample size of 85-106 early and 140-210 advanced patients, respectively. The study was not powered for a comparison between PET1 and PET2 PV. Survival curves were depicted using Kaplan-Meier plots. For evaluation of the PV of interim PET1, the PFS events were used. Only patients without treatment change entered the analysis of PV of iPETs. CIs for the PVs were the standard logit CI. The Cox proportional hazard regression analysis was used to evaluate the hazard ratio (HR) regarding PFS events between different treatment groups. Binary and overall concordance between reviewers' rates were calculated using Fleiss' kappa index. All data analyses were carried out using the statistical software package StatSoft. Inc. STATISTICA, version 12.0.
Results
Thirty-five of 345 registered patients were excluded from the analysis for absent/poor-quality images, resulting in 310 assessable patients with early (106) and advanced (204) cHL. Median age at diagnosis was 30.8 (18-80) years. Clinical characteristics of patients are given in Table 1 . All 310 patients had a (iPET1), at a median of 12 (7-21) days and 198 patients had additional PET after the second ABVD cycle (iPET2) at a median of 13 days (7-28) after preceding ABVD dose. Six patients with iPET(+) had no iPET2 carried out for treating physician decision. The median follow-up for surviving patients was 44.7 (12.7-90.2) months.
Response to ABVD 6 RT treatment
The overall workflow of patients across the study is shown in the consort diagram in Figure 1 . Twenty-four patients, who had their treatment intensified because of positive iPET1 (2 patients) or iPET2 (22 patients) and/or clinical symptoms of active HL were excluded from the response analysis. Complete response or complete metabolic remission (CMR) was achieved in 286 patients treated per-protocol: 98/102 (96%) with early and 151/184 (82%) with advanced-stage disease. Partial response (PR) was documented in 1 (1%) early and 7 (4%) advanced stage patients, whereas no response (NR) was reported in 3 (3%) early and 24 (13%) advanced stage patients. In four patients, end of therapy evaluation was not carried out due to early death.
All four early and 25/31 advanced patients who did not achieve CR progressed. During a median follow-up of 43 (15- Table 2 .
Response to treatment according to iPET1 results was assessed in 218 iPET1(À) patients (87 early and 131 advanced) and 68 iPET1(þ) patients (15 early and 53 advanced). Among patients with early stages and iPET1(À), only 4/87 had a PFS event (1 progression, 3 relapses) resulting with NPV 95% (95% CI: 91-98), whereas 5/15 with iPET1(þ) experienced events (3 progressions, 2 relapses out of whom 1 patient died) resulting with PPV 33% (95% CI: 18-53). Among iPET1(À) advanced-stage patients, 21/131 experienced a PFS event (10 progressed and 2 of them died, 5 relapsed and 2 of them died while 6 died from unrelated to HL reasons) resulting with NPV 84% (95% CI: 79-97). Among iPET1(þ) advanced patients, 22/53 had a PFS event: 10 progressed and 4 of them died, 11 relapsed and 3 of them died, and 1 died not from HL corresponding to PPV 42% (95% CI: 32-52). The 3-Y PFS for iPET1(À) early and advanced patients was 0.94 (95% CI: 0.86-0.99) and 0.84 (95% CI: 0.78-0.91), respectively; for iPET1(þ) was 0.59 (95% CI: 0.27-0.89) for early and 0.57 (95% CI: 0.43-0.71) for advanced stages (Figure 2A and B) .
Interim PET2 results and response to treatment according to iPET2 results, PFS, PPV and NPV Altogether iPET2 was carried out in 198/310 (64%) patients: 57 early and 141 advanced and was scored 1-3 in 51/57 (89%), and 4-5 in 6/57 (11%) of patients with early and in 106/141 (75%), and 35/141 (25%) of patients with advanced stage, respectively. Response to treatment according to iPET2 results was assessed excluding 22 patients (4 early and 18 advanced) with interim treatment escalation resulting in 152 iPET2(À) patients (50 early and 102 advanced) and 24 iPET2(þ) patients (3 early and 21 advanced) eligible for analysis. Among patients with early stage and iPET2(À), only 2/50 experienced a PFS event (2 progressions), whereas all 3 patients with iPET2(þ) did (1 progression, 2 relapses) out of whom 1 patient died resulting with NPV 96% (95% CI: 89-98) and PPV 100%. Among patients with advanced stages and iPET2(À), 18/102 experienced a PFS event (8 progressed, out of whom 1 died, 6 relapsed, out of whom 2 died, and 4 died, not from HL progression) corresponding to NPV of 82% (95% CI: 78-86) whereas 12/21 iPET2(þ) patients had treatment failure: 6 progressed, out of whom 3 died, 6 relapsed, out of whom 1 died resulting with PPV 57% (95% CI: 38-74). The 3-Y PFS for early and advanced stages with iPET2(À) was 0.96 (95% CI: 0.91-1) and 0.82 (95% CI: 0.74-0.89), respectively, whereas for patients with iPET2(þ) was 0 and 0.4 (95% CI: 0.18-0.63), respectively.
Kinetics of PET response
The kinetics of iPET response, assessed in 198 patients who underwent both iPET1 and iPET2, is summarized in supplemen tary Table S2 , available at Annals of Oncology online. All 116 patients with iPET1(À) remained negative in iPET2 (fast responders). Out of 82 with iPET1(þ), 41 became negative in iPET2 (slow responders), and 41 stayed positive (nonresponders). Fast responders (114) experienced 13 PFS events (7 relapses and 6 deaths for recurring disease). Among 38 slow responders only 7 had PFS event (1 death and 6 progressions) whereas 24 non-responders had 15 PFS events (15 progressed out of whom 5 died). Clinical characteristics of relapsing PET1 negative patients is shown in supplementary Table S3 , available at Annals of Oncology online.
Results of expert panel reviewing
Upon BICR, 27 iPET1 results were reclassified as follows: 14 from (þ) to (À) and 13 from (À) to (þ). Upon consensus review, the agreement was reached in all cases. Fleiss' kappa indicator of the inter-observer agreement between reviewers on evaluating positive versus negative interim PET scans was 0.73.
Discussion
Our study is the largest prospective observational trial exploring the predictive role of iPET after the first ABVD cycle in cHL patients. The final results of iPET1 scoring showed a clear difference between patients with early and advanced stages, with twice more positive scans in the latter group. This uneven score distribution reflects the difference in the biology of the disease between early and advanced stages.
We hypothesized that iPET1(À) patients would have the best outcome, with a high NPV both for patients with early and advanced stage. Indeed we were able to demonstrate a very good prognosis of iPET1(À) patients, showing a 3-Y PFS of 0.88, with the best result for early patients (0.94), and lower than expected (0.84) for advanced patients. Patients enrolled to the study but excluded from iPET dependent response due to treatment intensification Figure 1 . The consort diagram of the study.
The kinetics of HL response to ABVD with a sequential PET scanning explored in our study again highlight the diversity of HL patients. First, out of 198 patients scanned both after 1 and 2 ABVD courses, 116 patients had both iPET scan negative, irrespective of final treatment outcome. This is probably one of the most relevant results of our study, making us confident that a iPET1(À) heralds a negative iPET2.
Second important point, half of iPET1(þ) patients (both in early and advanced group) reverted to a negative scan, just after the following cycle (iPET2À). This allowed the identification of three types of patients: fast responders, slow responders and nonresponders with: both negative, positive/negative or both positive iPETs, respectively. The last cohort showed a significantly worse probability for 3-Y PFS (0.34) compared with the other two patient cohorts (0.88 and 0.79, respectively), confirming that nonresponders require an early switch to treatment more effective than ABVD. Fast responders had the best outcome; nevertheless Excluding patients with interim treatment escalation. $10% of them experience treatment failure. Slow responders experience still low (18%) but relatively more PFS events than fast responders (11%).
The results of our study allow discussing the role and timing of iPETs in HL treatment. We hypothesized that iPET1 may predict chemosensitivity better than iPET2: this would have increase clinical effectiveness of treatment escalation or reduction before tumor chemoresistance appearance.
Neither goal was completely met. First, PPV of iPET1 (%40%) was much lower than iPET2 (%60%) and the published results of iPET2, which are in the range 73%-90% [10] [11] [12] [13] [14] . The only other published paper using PET/CT exploring the PVs of iPET1 reported almost the same PPV (41%) at 2 years [15] . PPV of iPET1 was low because half of the iPET1(þ) patients became iPET2(À); therefore, iPET2 is much more suitable for predicting treatment. On the other hand, PPV of iPET2 in our study was underestimated due to exclusion of iPET2(þ) patients with treatment intensification. Second, and more importantly, the NPV of iPET1 was comparable with iPET2 reported by others. For example NPV of iPET1 (95%) in early stage patients is almost identical to a recently reported NPV of iPET2 (96%) in a group of 246 patients with a median follow-up of 46 months [16] . The comparison of NPV of iPET1 to iPET2 in our group of early patients should be mitigated because some events happened in patients with only iPET1. In a bigger group of advanced patients, NPV of iPET1 (84%) was little better than iPET2 (82%) but still very similar to that observed for iPET2 in most of the recently reported large cohort trials (%80%) [12] [13] [14] 17] . Similar NPVs of iPET1 and iPET2 indicate a comparable treatment failure incidence in patients with iPET1(À) and iPET2(À). However, as no patient with iPET1(À) became iPET2(þ) the failures occurring in slow responders [iPET1(þ)iPET2(À)] obviously decrease (although slightly, due to low number of events) NPV of iPET2. This observation might be important for studies aiming at treatment de-escalation that should enroll patients with the best prognosis.
The third and surprising observation regarding iPET1 is the unexpected relatively high incidence of treatment failure in patients with a negative iPET1. Early reports suggested a much higher (90%-100%) NPV of iPETs [3, 5, 6, 10] . Quite recently, Hutchings et al. reported a very high (98%) NPV of iPET1 [15] . The reasons for this discrepancy are not clear but might be related to the different prevalence of very early stage in both studies. The prevalence of very limited disease (IA) in Hutchings series (8%) and in our study (1%) is clearly skewed. As the most relapses do occur in stage II in both early favorable and early unfavorable groups [18] , and taking into account the relatively low number of patients scanned twice in Hutching's study (N ¼ 89), this skewed prevalence could make the difference.
The additional but important goal of our study was to implement standardization of PET imaging and to improve the expertise of Polish nuclear medicine physicians. The design of our observational prospective study was unique in this aspect because it allowed free transfer of knowledge between more and less experienced reviewers and also local nuclear medicine specialists using the academic platform. The good final inter-observer-agreement among Italian and Polish reviewers was comparable with that found in similar studies (IVS [11] , HD0607 [17] ) and confirmed that central PET review is feasible and that the DS is reproducible for the interpretation of iPET scans.
To conclude, our data provide strong arguments that the optimal timing for iPET scanning during ABVD in a PET-adapted treatment escalation strategy is after the second cycle. It has a high PPV, which is required for treatment escalation strategies, and an acceptable NPV. Nevertheless, due to its slightly higher NPV, iPET1 could be more suitable for trials exploring the role of treatment de-escalation, both in early and advanced stage disease.
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